Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Pat Ault"'
Autor:
Alfonso Quintás-Cardama, Taghi Manshouri, Matjaz Sever, Hagop M. Kantarjian, Jorge E. Cortes, Carlos E. Bueso-Ramos, Roberto Nussenzveig, Srdan Verstovsek, Josef T. Prchal, Pat Ault
Publikováno v:
International Journal of Hematology. 90:58-63
Polycythemia vera (PV) is a chronic myeloproliferative neoplasm (MPN) characterized by excessive production of red blood cells. Patients with PV are at a risk of thrombosis, bleeding, and transformation to myelofibrosis or acute myeloid leukemia. The
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3502fbb0bfb3ac2ab6d22a2a9c5e2e8
https://doi.org/10.1007/s12185-009-0345-y
https://doi.org/10.1007/s12185-009-0345-y
Autor:
Farhad Ravandi, Animesh Pardanani, Srdan Verstovsek, Hagop M. Kantarjian, Jorge E. Cortes, Carlos Bueso-Ramos, Alfonso Quintás-Cardama, Taghi Manshouri, Pat Ault, Raja Luthra, Ayalew Tefferi
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 15(1)
Purpose: Patients with hypereosinophilic syndrome (HES) or chronic eosinophilic leukemia (CEL) that are refractory to standard therapies are difficult to manage and have significantly shortened life expectancy. Experimental Design: CD52 is a surface
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56538bc21d85456cb99cd2e544bd36a5
https://pubmed.ncbi.nlm.nih.gov/19118067
https://pubmed.ncbi.nlm.nih.gov/19118067
Autor:
Yesid Alvarado, Hillary Prescot, Hagop M. Kantarjian, Jorge E. Cortes, Pat Ault, Jeff Bryan, Carmen Fava
Background: Imatinib plasma levels have been reported to correlate with response to therapy and possibly toxicity (Larson et al, Blood 2008; Picard et al, Blood 2007). These studies included patients taking standard dose, once daily imatinib. However
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31f588d652f6c9fd96b4e69a1e6a1501
http://hdl.handle.net/2318/92831
http://hdl.handle.net/2318/92831
Publikováno v:
Clinical Leukemia. 1:357-358
Dasatinib is a new tyrosine kinase inhibitor which is approved by the FDA for the treatment of patients with chronic myeloid leukemia (CML) resistant or intolerant to imatinib. Dasatinib can cause fluid retention in some patients, leading to peripher
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::58fb6377db872131390d78c43dce5bb8
https://doi.org/10.3816/clk.2007.n.030
https://doi.org/10.3816/clk.2007.n.030
Autor:
Jorge Cortes, Farhad Ravandi, Guillermo Garcia-Manero, Srdan Verstovsek, Gautam Borthakur, Zeev Estrov, Elizabeth M. Burton, Pat Ault, Susan O’Brien, Mary Beth Rios, Hagop M. Kantarjian, Dushyant Verma
Publikováno v:
Blood. 112:2125-2125
Background: Success of tyrosine kinase inhibitors (TKIs) (imatinib, dasatinib, nilotinib, bosutinib) in chronic myeloid leukemia (CML) has given patients (pts) hope for a long disease free survival, and with increased survival, may be some late effec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7ef76f193049db7f4f5d2f2996600997
https://doi.org/10.1182/blood.v112.11.2125.2125
https://doi.org/10.1182/blood.v112.11.2125.2125
Autor:
Ayalew Tefferi, Srdan Verstovsek, Pat Ault, Francis J. Giles, Farhad Ravandi-Kashani, Animesh D. Pardanani, Alfonso Quintás-Cardama, Hagop M. Kantarjian, Jorge E. Cortes
Publikováno v:
Blood. 108:4902-4902
Idiopathic HES is a myeloproliferative disorder (MPD) characterized by persistent overproduction of eosinophils resulting in organ damage. In a small subset of patients (pts), the disease is caused by the FIP1L1-PDGFR-α fusion tyrosine kinase. Its e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cb9dfdaffbd472efa6b00315b34d1b88
https://doi.org/10.1182/blood.v108.11.4902.4902
https://doi.org/10.1182/blood.v108.11.4902.4902
Autor:
Emil J. Freireich, Hagop M. Kantarjian, Jorge E. Cortes, Mary Beth Rios, Stefan Faderl, Pat Ault, Susan O'Brien, Charles Koller
Publikováno v:
Blood. 106:1104-1104
Although pts with CML receiving IM therapy are required to practice contraception while on therapy, there are isolated case reports of conception and pregnancy while on therapy. Here we present our experience with 18 pts who conceived while on IM the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::72a0131f555db968611c4f7da37282ba
https://doi.org/10.1182/blood.v106.11.1104.1104
https://doi.org/10.1182/blood.v106.11.1104.1104